Allogeneic Stem Cell Transplantation With 3-days Busulfan Plus Fludarabine as Conditioning in Patients With Relapsed or Refractory T-, NK/T-cell Lymphomas

Who is this study for? Patients with relapsed or refractory T-, NK/T-cell lymphomas
What treatments are being studied? Busulfan+Fludarabine
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

Relapsed and refractory T-cell lymphomas have been reported to have dismal outcomes. The role of allogeneic stem cell transplantation have been demonstrated in these patients. This clinical trial is studying the efficacy and safety of busulfan plus fludarabine as conditioning therapy followed by allogeneic stem cell transplantation (Allo-SCT) in T- and NK/T-cell lymphoma patients who have relapsed or are refractory to previous chemotherapies including autologous transplantation.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 19
Maximum Age: 65
Healthy Volunteers: t
View:

• Age 19 - 65

• Histologically confirmed T or NK cell lymphomas :

‣ anaplastic large cell lymphoma

⁃ angioimmunoblastic T-cell lymphoma,

⁃ peripheral T-cell lymphoma, NOS

⁃ NK/T-cell lymphoma

• Relapsed after or refractory to one or more of previous chemotherapy including frontline autologous HSCT.

• At least one measured lesion using conventional CT or PET CT at the time of relapse after or refractory to one or more of previous chemotherapy and before salvage chemotherapy

• Complete or Partial response after short cycles of salvage chemotherapy

• Patients who have HLA full-match (8/8 in HLA-A, B, C, DR by DNA high-resolution technique) or one-locus mismatch (7/8) sibling, or unrelated bone marrow or peripheral blood or cord blood stem cell donors

• ECOG performance status ≤ 2

• Charlson Comorbidity Index (CCI) before HSCT ≤ 3

• Adequate renal function : serum creatinine level \< 2.0 mg/dL

⁃ Adequate liver function :

∙ Transaminase (AST/ALT) \< 3 X upper normal value (or \< 5 x ULN in the presence of lymphoma involvement of the liver)

‣ Total bilirubin \< 2 X upper normal value (or \< 5 x ULN in the presence of NK/T involvement of the liver)

⁃ Cardiac ejection fraction ≥ 50 % as measured by MUGA or 2D ECHO without clinically significant abnormality

⁃ No clinically significant infection

⁃ No clinically significant bleeding symptoms or sign

⁃ Patients who decided to participate in this study and signed for a written consent

Locations
Other Locations
Republic of Korea
Dong-A University
RECRUITING
Busan
Keimyung University Dongsan Medical Center
RECRUITING
Daegu
Contact Information
Primary
Young Rok Do, MD., Ph.D.
dyr1160@dsmc.or.kr
+82-10-3541-1160
Backup
Ji Hyun Lee, MD., Ph.D.
hidrleejh@dau.ac.kr
+82-10-9397-5694
Time Frame
Start Date: 2016-12
Estimated Completion Date: 2027-12
Participants
Target number of participants: 34
Treatments
Experimental: Experimental Arm
Conditioning chemotherapy: Fludarabine and Busulfan followed by Allogeneic stem cell transplantation
Sponsors
Leads: Keimyung University Dongsan Medical Center
Collaborators: Otsuka Pharmaceutical Co., Ltd.

This content was sourced from clinicaltrials.gov

Similar Clinical Trials